Cdk5 Signaling in Neurodevelopment and Disease

Cyclin-dependent kinase 5 (Cdk5) is a proline-directed serine/threonine kinase whose activity is restricted primarily to post-mitotic neurons through association with regulatory subunits p35 and p39. During brain development, Cdk5 orchestrates neuronal migration, axon guidance and synaptic plasticity by phosphorylating cytoskeletal proteins and modulating vesicle trafficking. Under physiological conditions, precise control of Cdk5 activity supports learning, memory and circadian rhythms. However, proteolytic cleavage of p35 to p25 yields a hyperactive, mislocalised kinase that contributes to aberrant phosphorylation of substrates, mitochondrial dysfunction and DNA damage. Such dysregulation is implicated in a spectrum of neurological disorders, including Alzheimer’s disease, Parkinson’s disease and traumatic brain injury, as well as in certain brain tumours. Beyond its classical neuronal roles, Cdk5 influences neuroinflammation, neurovascular integrity and the biogenesis of microRNAs, underscoring its broad impact on central nervous system health. Emerging evidence highlights the potential for selectively modulating Cdk5 complexes to restore normal signalling in neurodegenerative and acute injury contexts, offering new avenues for therapeutic intervention.

Research from Nature Portfolio

Recent studies have elucidated a mechanistic axis in which aberrant Cdk5 activation promotes glioblastoma progression through a nuclear ubiquitination pathway. Growth factor-stimulated Cdk5 directly phosphorylates the ubiquitin ligase TRIM59, triggering its cis–trans isomerisation and transport into the nucleus. Once inside the nucleus, TRIM59 targets the histone variant macroH2A1 for ubiquitination and proteasomal degradation. Loss of macroH2A1 releases repression of oncogenic STAT3 signalling, thereby enhancing tumour cell proliferation and invasiveness. Pharmacological or genetic inhibition of the Cdk5–TRIM59 interaction restores macroH2A1 levels, attenuates STAT3 activation and markedly reduces intracranial tumour growth in preclinical models. These findings reveal a novel Cdk5-driven epigenetic mechanism that links kinase signalling to chromatin remodelling and identify the Cdk5–TRIM59 axis as a promising target in high-grade brain malignancies.

Cdk5 Signaling in Neurodevelopment and Disease publication trend

The graph below shows the total number of articles in cdk5 signaling in neurodevelopment and disease across all publications each year (not limited to Nature Index journals).

Technical terms

Cyclin-dependent kinase 5 (Cdk5): A serine/threonine kinase active in neurons upon binding to p35 or p39 regulators.

p35/p39: Neuron-specific activators of Cdk5 that determine its subcellular localisation and substrate specificity.

p25: A calpain-mediated cleavage product of p35 that generates hyperactive, mislocalised Cdk5.

Phosphorylation: The enzymatic addition of a phosphate group to a protein, modulating its activity or interactions.

Ubiquitination: A post-translational modification in which ubiquitin is attached to a substrate protein, often marking it for degradation.

MacroH2A1: A histone variant whose removal from chromatin influences gene expression programmes.

Drosha: An RNase III enzyme critical for the initial processing step of microRNA biogenesis.

STAT3: A transcription factor activated by phosphorylation that controls genes involved in survival and proliferation.

References

1. Maintaining Drosha expression with Cdk5 inhibitors as a potential therapeutic strategy for early intervention after TBI. Experimental & Molecular Medicine (2024).
2. Three decades of Cdk5. Journal of Biomedical Science (2021).
3. CDK5-dependent phosphorylation and nuclear translocation of TRIM59 promotes macroH2A1 ubiquitination and tumorigenicity. Nature Communications (2019).
4. Cyclin-dependent Kinase 5 Regulates Endothelial Cell Migration and Angiogenesis. Journal of Biological Chemistry (2010).